HomeDolutegravir SodiumDolutegravir Sodium + Dolutegravir

Does Dolutegravir Sodium Interact with Dolutegravir?

Dolutegravir Sodium and Dolutegravir have a unknown drug interaction according to U.S. FDA drug labeling data. ( 4 , 7 ) • Drugs that are metabolic inducers may decrease the plasma concentrations of dolutegravir. ( 7.3 ) 7.1 Effect of Dolutegravir on the Pharmacokinetics of Other Agents In vitro, dolutegravir inhibited the renal organic cation transporters, OCT2 (IC 50 = 1.93 microM) and multidrug and toxin extrusion transporter (MATE) 1 (IC 50 = 6.34 microM). In vivo, dolutegravir inhibits tubular secretion of creatinine by inhibiting OCT2 and potentially MATE1. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Unknown
Management
Consult your pharmacist
Data Source
U.S. FDA via OpenFDA

What To Tell Your Doctor or Pharmacist

If you are taking Dolutegravir Sodium and your doctor is considering prescribing Dolutegravir (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Never stop or change either medication without first consulting your healthcare provider
💊 Dolutegravir Sodium(Tivicay)+💊 Dolutegravir

Severity & Interaction Details

ℹ️
unknown
Interaction documented — severity unclassified
The FDA label notes an interaction but the severity is not classified in our dataset.
Severity scale
MinorContra
On record
Yes
Drug A class
Drug B class
Source
FDA drug label - dolutegravir sodium

What this means in plain English

( 4 , 7 ) • Drugs that are metabolic inducers may decrease the plasma concentrations of dolutegravir. ( 7.3 ) 7.1 Effect of Dolutegravir on the Pharmacokinetics of Other Agents In vitro, dolutegravir inhibited the renal organic cation transporters, OCT2 (IC 50 = 1.93 microM) and multidrug and toxin extrusion transporter (MATE) 1 (IC 50 = 6.34 microM). In vivo, dolutegravir inhibits tubular secretion of creatinine by inhibiting OCT2 and potentially MATE1.

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Dolutegravir Sodium and Dolutegravir against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.